CL2014003331A1 - Formas cristalinas de un modulador de receptor de androgeno - Google Patents

Formas cristalinas de un modulador de receptor de androgeno

Info

Publication number
CL2014003331A1
CL2014003331A1 CL2014003331A CL2014003331A CL2014003331A1 CL 2014003331 A1 CL2014003331 A1 CL 2014003331A1 CL 2014003331 A CL2014003331 A CL 2014003331A CL 2014003331 A CL2014003331 A CL 2014003331A CL 2014003331 A1 CL2014003331 A1 CL 2014003331A1
Authority
CL
Chile
Prior art keywords
crystal forms
androgen receptor
receptor modulator
iluorometiipiridin
mammer
Prior art date
Application number
CL2014003331A
Other languages
English (en)
Inventor
Nicholas D Smith
Mark R Herbert
Quathek Querfelli
Anna Dilhas
Original Assignee
Aragon Pharmaceuticals Inc
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003331(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc, Sloan Kettering Inst Cancer filed Critical Aragon Pharmaceuticals Inc
Publication of CL2014003331A1 publication Critical patent/CL2014003331A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMAS CRISTALINAS DE 4-[7-(6-CIANO-5-TRI ILUOROMETIIPIRIDIN-3-II)-8-OXO-6-TIOXO-5,7-DIAZASPIRO[3.4]OCT-5-II]-2-FLUORO-N-METILBENZAMIDA, MODULADOR DE RECEPTOR DE ANDROGENO; COMPOSICION FARMACEUTICA; Y SU USO PARA EL TRATAMIENTO DEL CANCER DE PROSTATA EN UN MAMIFERO.
CL2014003331A 2012-06-07 2014-12-05 Formas cristalinas de un modulador de receptor de androgeno CL2014003331A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07

Publications (1)

Publication Number Publication Date
CL2014003331A1 true CL2014003331A1 (es) 2016-03-04

Family

ID=49712550

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003331A CL2014003331A1 (es) 2012-06-07 2014-12-05 Formas cristalinas de un modulador de receptor de androgeno

Country Status (45)

Country Link
US (10) US9481663B2 (es)
EP (4) EP3533792B1 (es)
JP (3) JP6182209B2 (es)
KR (2) KR102195916B1 (es)
CN (3) CN105693692A (es)
AU (3) AU2013271751B2 (es)
BR (1) BR112014030678A2 (es)
CA (4) CA2875767C (es)
CL (1) CL2014003331A1 (es)
CO (1) CO7240407A2 (es)
CR (2) CR20190331A (es)
CY (4) CY1120393T1 (es)
DK (3) DK3348553T3 (es)
EA (3) EA028791B1 (es)
EC (1) ECSP14030098A (es)
ES (3) ES2670683T3 (es)
FR (1) FR21C1050I2 (es)
GT (1) GT201400283A (es)
HK (2) HK1210175A1 (es)
HR (3) HRP20180902T1 (es)
HU (4) HUE050357T2 (es)
IL (5) IL320522A (es)
IN (1) IN2014DN10084A (es)
LT (4) LT2858985T (es)
LU (1) LUC00236I2 (es)
ME (2) ME03815B (es)
MX (1) MX356754B (es)
MY (1) MY187500A (es)
NI (1) NI201400142A (es)
NL (1) NL301144I2 (es)
NO (1) NO2021046I1 (es)
NZ (2) NZ702203A (es)
PE (3) PE20200795A1 (es)
PH (2) PH12014502714B1 (es)
PL (3) PL2858985T3 (es)
PT (3) PT2858985T (es)
RS (3) RS60617B1 (es)
SG (3) SG10201610248SA (es)
SI (3) SI3348553T1 (es)
SM (3) SMT201800311T1 (es)
TR (1) TR201808939T4 (es)
TW (1) TWI532732B (es)
UA (2) UA115665C2 (es)
WO (1) WO2013184681A1 (es)
ZA (1) ZA201500076B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE50642E1 (en) 2012-09-26 2025-10-21 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP2791128A4 (en) 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
RS60617B1 (sr) * 2012-06-07 2020-09-30 Aragon Pharmaceuticals Inc Kristalni oblici modulatora receptora androgena
TWI673051B (zh) 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
DK2945628T3 (da) * 2013-01-15 2020-05-04 Aragon Pharmaceuticals Inc Androgen receptormodulator i kombination med abirateronacetat og prednison til behandling af prostatacancer
CN106795152B (zh) * 2014-08-26 2020-01-31 安斯达尔生物技术有限责任公司 蛋白激酶抑制剂
US10285948B2 (en) 2014-12-05 2019-05-14 Janssen Pharmaceutica Nv Anticancer compositions
EA201791222A1 (ru) * 2014-12-05 2017-09-29 Арагон Фармасьютикалз, Инк. Противораковые композиции
HUE051888T2 (hu) 2014-12-05 2021-03-29 Aragon Pharmaceuticals Inc Rákellenes készítmények
MX2017008050A (es) 2014-12-19 2018-01-18 Lutron Electronics Co Accesorio de iluminacion multicanal que tiene controladores de diodo emisor de luz.
JP2019517497A (ja) 2016-06-03 2019-06-24 アラゴン ファーマシューティカルズ，インコーポレイテッド 抗癌性組成物
US11149017B2 (en) 2016-12-13 2021-10-19 Watson Laboratories Inc. Solid state forms of apalutamide
MX2020003845A (es) 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
WO2019135254A1 (en) 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
WO2019242439A1 (zh) * 2018-06-20 2019-12-26 苏州科睿思制药有限公司 Arn-509的晶型及其制备方法和用途
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it) 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
US20220281836A1 (en) * 2019-08-22 2022-09-08 Dr. Reddy's Laboratories Limited Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) * 2019-09-20 2019-12-20 武汉大学 一种阿帕鲁胺化合物及其药物制剂
EP4541786A3 (en) 2020-09-04 2025-08-06 Synthon B.V. Improved process for preparation of apalutamide
CN112679468A (zh) * 2021-01-05 2021-04-20 四川科伦药物研究院有限公司 阿帕他胺的晶体形式、制备方法和用途
WO2023143090A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN116332907A (zh) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 一种无定形阿帕他胺的制备方法
WO2025153768A1 (en) * 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
ES2689292T3 (es) 2006-03-27 2018-11-13 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
NZ572374A (en) 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
SG10201907588XA (en) 2010-02-16 2019-09-27 Aragon Pharmaceuticals Inc Androgen Receptor Modulators And Uses Thereof
RS60617B1 (sr) * 2012-06-07 2020-09-30 Aragon Pharmaceuticals Inc Kristalni oblici modulatora receptora androgena
WO2019242439A1 (zh) 2018-06-20 2019-12-26 苏州科睿思制药有限公司 Arn-509的晶型及其制备方法和用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE50642E1 (en) 2012-09-26 2025-10-21 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Also Published As

Publication number Publication date
CY2021032I2 (el) 2022-03-24
HK1226066A1 (zh) 2017-09-22
HUE038082T2 (hu) 2018-09-28
PE20200725A1 (es) 2020-07-21
SI2858985T1 (sl) 2018-12-31
SMT202100355T1 (it) 2021-07-12
US10556882B2 (en) 2020-02-11
US20170001977A1 (en) 2017-01-05
CR20190331A (es) 2019-11-12
CY1124831T1 (el) 2022-03-24
ECSP14030098A (es) 2016-01-29
EP2858985B1 (en) 2018-04-18
EA201992010A1 (ru) 2020-01-24
SG10201610248SA (en) 2017-02-27
NI201400142A (es) 2016-12-02
US10934271B2 (en) 2021-03-02
AU2017200298B2 (en) 2017-09-28
ME03815B (me) 2021-04-20
LT3348553T (lt) 2020-09-25
JP6345821B2 (ja) 2018-06-20
HUE054595T2 (hu) 2021-09-28
PL3348553T3 (pl) 2021-02-08
US20180258067A1 (en) 2018-09-13
LT2858985T (lt) 2018-09-25
US20190241539A1 (en) 2019-08-08
IL267608A (en) 2019-08-29
CY2021032I1 (es) 2022-03-24
IL320522A (en) 2025-06-01
IL267608B1 (en) 2025-06-01
MX356754B (es) 2018-06-11
NZ717683A (en) 2018-04-27
CN104619692A (zh) 2015-05-13
IL275413A (en) 2020-07-30
HUS2100047I1 (hu) 2021-11-29
JP6182209B2 (ja) 2017-08-16
EA201791592A1 (ru) 2018-01-31
SMT201800311T1 (it) 2018-07-17
PT2858985T (pt) 2018-07-10
HRP20201387T1 (hr) 2020-11-27
RS60617B1 (sr) 2020-09-30
JP2015518890A (ja) 2015-07-06
JP2018141009A (ja) 2018-09-13
IL259738B (en) 2021-06-30
CA3114726A1 (en) 2013-12-12
EA028791B1 (ru) 2017-12-29
PE20200795A1 (es) 2020-08-10
EP3348553A1 (en) 2018-07-18
US12018008B2 (en) 2024-06-25
WO2013184681A1 (en) 2013-12-12
IL267608B2 (en) 2025-10-01
UA123142C2 (uk) 2021-02-24
CY1123427T1 (el) 2021-12-31
US9994545B2 (en) 2018-06-12
EP2858985A1 (en) 2015-04-15
EA201492272A1 (ru) 2015-05-29
EA033956B1 (ru) 2019-12-13
CA3055660A1 (en) 2013-12-12
US20250092011A1 (en) 2025-03-20
AU2013271751A1 (en) 2014-12-18
HRP20210909T1 (hr) 2021-09-03
PT3533792T (pt) 2021-06-07
US10766875B2 (en) 2020-09-08
TW201402561A (zh) 2014-01-16
CA3008345C (en) 2019-10-22
TR201808939T4 (tr) 2018-07-23
CA3008345A1 (en) 2013-12-12
PH12016501470A1 (en) 2017-07-10
PH12014502714A1 (en) 2015-02-02
LUC00236I2 (es) 2025-02-03
AU2017279807A1 (en) 2018-01-25
EP3348553B1 (en) 2020-07-08
TWI532732B (zh) 2016-05-11
ES2809738T3 (es) 2021-03-05
PT3348553T (pt) 2020-09-28
KR20190132543A (ko) 2019-11-27
EP2858985A4 (en) 2016-05-25
US9481663B2 (en) 2016-11-01
KR20150021993A (ko) 2015-03-03
US20200354335A1 (en) 2020-11-12
LTPA2021525I1 (es) 2021-11-25
EP3533792B1 (en) 2021-05-05
US20150133481A1 (en) 2015-05-14
FR21C1050I2 (fr) 2024-05-24
LTC3533792I2 (es) 2024-07-10
US10308630B2 (en) 2019-06-04
SI3533792T1 (sl) 2021-11-30
AU2013271751B2 (en) 2017-02-23
NL301144I2 (nl) 2025-03-20
ES2670683T3 (es) 2018-05-31
CO7240407A2 (es) 2015-04-17
CN113135892A (zh) 2021-07-20
SG11201408140QA (en) 2015-01-29
EP3533792A1 (en) 2019-09-04
RS61988B1 (sr) 2021-07-30
ME03081B (me) 2019-01-20
HRP20180902T1 (hr) 2018-08-24
US20200115361A1 (en) 2020-04-16
NO2021046I1 (no) 2021-11-02
UA115665C2 (uk) 2017-12-11
US20210163441A1 (en) 2021-06-03
DK3533792T3 (da) 2021-06-28
PH12016501470B1 (en) 2021-12-10
FR21C1050I1 (fr) 2021-12-10
KR102195916B1 (ko) 2020-12-30
SG10201610249TA (en) 2017-02-27
US20260109683A1 (en) 2026-04-23
HK1210175A1 (en) 2016-04-15
GT201400283A (es) 2017-07-03
MY187500A (en) 2021-09-24
HUE050357T2 (hu) 2020-11-30
PL3533792T3 (pl) 2021-11-29
CR20140549A (es) 2015-04-06
PH12014502714B1 (en) 2015-02-02
NZ702203A (en) 2016-09-30
CN105693692A (zh) 2016-06-22
EP3922629A1 (en) 2021-12-15
JP2017178923A (ja) 2017-10-05
IL236055A0 (en) 2015-02-01
PL2858985T3 (pl) 2018-09-28
SI3348553T1 (sl) 2020-11-30
BR112014030678A2 (pt) 2017-06-27
DK3348553T3 (da) 2020-07-27
AU2017279807B2 (en) 2018-11-08
US10526310B2 (en) 2020-01-07
PE20150631A1 (es) 2015-05-11
IL259738A (en) 2018-07-31
US20190330182A1 (en) 2019-10-31
KR102062024B1 (ko) 2020-01-03
SMT202000496T1 (it) 2020-11-10
LT3533792T (lt) 2021-07-26
MX2014015005A (es) 2015-09-04
IN2014DN10084A (es) 2015-08-21
CA2875767A1 (en) 2013-12-12
RS57370B1 (sr) 2018-08-31
ZA201500076B (en) 2016-10-26
CA2875767C (en) 2018-08-14
CY1120393T1 (el) 2019-07-10
AU2017200298A1 (en) 2017-02-02
DK2858985T3 (en) 2018-05-28
ES2875932T3 (es) 2021-11-11

Similar Documents

Publication Publication Date Title
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2015002932A1 (es) Inhibidores de proteína quinasa
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
CL2016001743A1 (es) Conjugados de anticuerpo-fármaco (adc) de duocarmicina para su uso en el tratamiento de cáncer de endometrio.
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
CY1123716T1 (el) Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2017011834A (es) Macrociclos peptidomimeticos y usos de los mismos.
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
CL2013001009A1 (es) Compuestos heterociclicos fusionados; composicion farmaceutica que los comprende, y uso en el tratamiento de un trastorno proliferativo tal como cancer.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
CR20110553A (es) Terapia complementaria contra el cáncer
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.